The Center for Biosimilars® recaps the top stories for the week of August 19, 2019.
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 19, 2019.
Number 5: AbbVie has gained approval for a Janus kinase inhibitor that is expected to help the company remain competitive in the immunology market after biosimilar adalimumab arrives in the United States in 2023.
Number 4: A teriparatide biosimilar has launched in Europe under the names Terrosa and Movimya.
Number 3: Researchers reported that a mandatory switch to biosimilar etanercept did not change overall healthcare utilization.
Number 2: A court has declined to halt Amgen’s sales of its biosimilar bevacizumab pending the outcome of an appeal.
Number 1: Starting on October 1, UnitedHealthcare will prefer Amgen’s anticancer biosimilars for its commercial and community plans.*
Finally, last week, our e-newsletter asked how you think authorized biologics could impact the US biosimilars market.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
*The biosimilars will not be preferred for Medicare Advantage plans.